We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -38.00 | -0.32% | 11,988.00 | 12,014.00 | 12,018.00 | 12,144.00 | 11,882.00 | 12,070.00 | 1,888,527 | 16:35:09 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.14 | 185.43B |
From Apr 2019 to Apr 2024
By Adria Calatayud
Circassia Pharmaceuticals PLC (CIR.LN) said Tuesday that it will exercise an option to acquire full U.S. commercial rights to Tudorza, a drug for chronic obstructive pulmonary disease.
The pharmaceutical company said it has issued a notice of option exercise to AstraZeneca PLC (AZN.LN), its partner in the development of the drug.
Completion of the option exercise, which is expected on Dec. 31, will trigger a $5 million payment, Circassia said. A deferred payment of $20 million will be payable upon approval of Duaklir--another drug for treatment of chronic obstructive pulmonary disease-- in addition to a deferred consideration of $100 million due under the agreement between AstraZeneca and Circassia.
Circassia shares at 1231 GMT were down 1.8% at 64.80 pence.
Write to Adria Calatayud at adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
December 11, 2018 07:54 ET (12:54 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
